Biocaptiva Limited

biocaptiva is developing the biocaptor, a revolutionary medical device which has the potential to transform liquid biopsy testing for cancer management, by improving early diagnosis and monitoring of disease and enhancing clinical trial data of cancer patients. the biocaptor captures up to 100x more cell free dna (cfdna) than a venous blood draw, yielding cfdna in high quality and quantity for testing, addressing the major challenge of liquid biopsy in cancer management. this will potentially allow the testing of a far greater number of cancer types and stages in a much wider range of patients. biocaptiva was founded in 2021 when it spun out from the university of edinburgh. biocaptiva is based in edinburgh and backed by archangels and scottish enterprise. for more information, please visit www.biocaptiva.com